Business Context and Reporting Period
Company: Apimeds Pharmaceuticals US, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Apimeds is a clinical-stage biopharmaceutical company developing Apitox, a purified bee venom-based toxin intended for the treatment of inflammation and pain associated with knee osteoarthritis (OA) and, potentially, multiple sclerosis (MS). The product is currently marketed in South Korea as "Apitoxin" by Apimeds Korea but is not yet FDA-approved in the United States. The Company is a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,389,990) | $(777,694) |
| Operating Expenses | $1,275,095 | $747,436 |
| Research & Development Expenses | $0 | $98,544 |
| General & Administrative Expenses | $1,275,095 | $648,892 |
| Cash and Cash Equivalents (End of Period) | $3,455 | $410,481 |
| Working Capital Deficit | $(1,011,277) | $298,760 |
| Accumulated Deficit | $(4,391,924) | $(3,001,934) |
| Total Liabilities | $1,371,178 | $390,207 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $612,296 (79%) year-over-year, primarily driven by a $626,203 increase in General and Administrative (G&A) expenses.
- G&A Expense Surge: G&A expenses rose from $648,892 in 2023 to $1,275,095 in 2024. This was attributed to a $329,322 increase in professional services (including pre-IPO and registration statement costs) and a $299,404 increase in payroll expenses for officers.
- R&D Cessation: Research and Development expenses dropped to $0 in 2024 from $98,544 in 2023, as the Company was not performing active R&D activities during the period.
- Liquidity Deterioration: Cash balances plummeted from $410,481 to $3,455. Net cash used in operating activities increased to $733,526 in 2024 from $627,790 in 2023.
- Debt Financing: The Company raised $326,500 in 2024 through financing activities, consisting of $250,000 in notes payable from related parties and $76,500 in cash advances.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the Company's ability to continue as a going concern. With only $3,455 in cash and an accumulated deficit of $4.4 million, existing resources are insufficient to satisfy operating needs for the next 12 months. Continued operations depend on obtaining additional financing.
- Clinical Development Strategy: The Company is focusing on a second Phase III trial for knee OA to meet FDA standards, targeting patients with grade 2, 3, and 4 OA. MS development is currently limited to non-registered corporate sponsorship studies.
- Regulatory Status: Apitox is not FDA-approved. The Company intends to file a Biologics License Application (BLA) following successful Phase III completion. The FDA previously highlighted concerns regarding study population size and data handling in prior trials.
- Internal Control Weaknesses: Management concluded that internal controls over financial reporting were not effective as of December 31, 2024, citing material weaknesses including a lack of documented procedures, segregation of duties, and review controls over journal entries.
- Related Party Dependence: The Company relies heavily on related parties (Apimeds Korea and Inscobee Inc.) for funding, intellectual property licensing, and debt financing. Significant debt obligations are convertible upon a "Qualified Offering."
Investor Verification Checklist
- Cash Runway: Verify the Company's ability to secure immediate financing given the $3,455 cash balance and substantial doubt regarding going concern status.
- Debt Conversion Terms: Review the terms of the convertible notes held by related parties (Inscobee/Apimeds Korea), specifically the conversion prices and triggers tied to a Qualified Offering.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Related Party Transactions: Scrutinize the 5% royalty agreement with Apimeds Korea and the concentration of debt and equity ownership among related entities.
- Phase III Trial Design: Confirm the specific design and FDA feedback regarding the upcoming Phase III trial for knee OA, as previous trials failed to meet FDA approval standards.